M
Muhammad Baluom
Researcher at Sunesis Pharmaceuticals
Publications - 10
Citations - 936
Muhammad Baluom is an academic researcher from Sunesis Pharmaceuticals. The author has contributed to research in topics: Fostamatinib & Syk. The author has an hindex of 9, co-authored 10 publications receiving 847 citations.
Papers
More filters
Journal ArticleDOI
R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation
Sylvia Braselmann,Vanessa Taylor,Haoran Zhao,Su Wang,Catherine Sylvain,Muhammad Baluom,Kunbin Qu,Ellen Herlaar,Angela Lau,Chi Young,Brian R Wong,Scott Lovell,Thomas Sun,Gary Park,Ankush Argade,Stipo Jurcevic,Polly Pine,Rajinder Singh,Elliott B. Grossbard,Donald G. Payan,Esteban Masuda +20 more
TL;DR: A first-inhuman study is reported showing that R406 is orally bioavailable, achieving exposures capable of inhibiting Syk-dependent IgE-mediated basophil activation and showing R406 potential for modulating Syk activity in human disease.
Journal ArticleDOI
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.
Frances Rena Bahjat,Polly Pine,Andrea Reitsma,Gail Cassafer,Gail Cassafer,Muhammad Baluom,Sunny Grillo,Betty Chang,Fei Fei Zhao,Donald G. Payan,Elliott B. Grossbard,David I. Daikh,David I. Daikh +12 more
TL;DR: It is demonstrated that a novel Syk-selective inhibitor prevents the development of renal disease and treats established murine lupus nephritis and suggest that Syk inhibitors may be of therapeutic benefit in human l upus and related disorders.
Journal ArticleDOI
Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation.
David J. Sweeny,Weiqun Li,Jeffrey Clough,Somasekhar Bhamidipati,Rajinder Singh,Gary Park,Muhammad Baluom,Elliott B. Grossbard,David Lau +8 more
TL;DR: The data indicate that the major fecal metabolite of R406 observed in humans is a product of a hepatic cytochrome P450-mediated O-demethylation and subsequent O- Demethylations and dehydroxylation by gut bacteria.
Journal ArticleDOI
Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen
John R. McLaughlin,Vadim Markovtsov,Hui Li,Steve Wong,Marina Gelman,Yanhong Zhu,Christian Franci,D. Wayne Lang,Erlina Pali,Joe Lasaga,Caroline M. R. Low,Feifei Zhao,Betty Chang,Tarikere Gururaja,Weiduan Xu,Muhammad Baluom,David J. Sweeny,David L. Carroll,Arvinder Sran,Sambaiah Thota,Manjeet Parmer,Angela Romane,George Clemens,Elliott B. Grossbard,Kunbin Qu,Yonchu Jenkins,Taisei Kinoshita,Vanessa Taylor,Sacha Holland,Ankush Argade,Rajinder Singh,Polly Pine,Donald G. Payan,Yasumichi Hitoshi +33 more
TL;DR: R763/AS703569 is a potent inhibitor of Aurora kinases and exhibited significant anti-proliferative activity against a wide range of tumor cells both in vitro and in vivo.
Journal ArticleDOI
Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
TL;DR: Fostamatinib demonstrates rapid and extensive conversion to R406, an inhibitor of SYK, and solid dosage forms of fostamatinIB overcome the challenge of low aqueous solubility of R406.